Search

Displaying results 3451 - 3460 of 10000 in total
  1. Drug

    Enzalutamide

    go.drugbank.com/drugs/DB08899
    ApprovedInvestigational

    [L40639] It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012. … [A252667,A252642] Due to a favorable pharmacological profile, a phase 1 study of enzalutamide was initiated in July 2007.

  2. Drug

    Mandelic acid

    go.drugbank.com/drugs/DB13218
    Approved

    Mandelic acid is an approved aromatic, alpha hydroxy acid [L5458]. Mandelic acid is used as an ingredient in cosmetics and drug products applied topically.

  3. Drug

    Amrubicin

    go.drugbank.com/drugs/DB06263
    Investigational

    In 2002, Amrubicin was approved and launched for sale in Japan based on Phase 2 efficacy data in both SCLC and NSCLC. … Amrubicin is a third-generation synthetic anthracycline currently in development for the treatment of small cell lung cancer. Pharmion licensed the rights to Amrubicin in November 2006.

  4. Target

    Cyclin-dependent kinases

    go.drugbank.com/bio_entities/BE0010231
    TargetHumans

    Component of the ternary complex, cyclin D/CDK4/CDKN1B, required for nuclear translocation and activity of the cyclin D-CDK4 complex … Phosphorylates SKA3 on multiple sites during mitosis which promotes SKA3 binding to the NDC80 complex and anchoring of the SKA complex to kinetochores, to enable stable attachment of mitotic spindle microtubules

    Synonyms: Mediator complex subunit CDK8, Tat-associated kinase complex catalytic subunit
  5. Drug

    Ancrod

    go.drugbank.com/drugs/DB05099
    ApprovedWithdrawn

    The defribrinogenation of blood results in an anticoagulant effect. … Currently, Viprinex®/ancrod is not approved or marketed in any country, but is being investigated as a stroke treatment in worldwide clinical trials. In January 2005, the U.S.

    Categories: Complex Mixtures
  6. Drug

    Bisoxatin

    go.drugbank.com/drugs/DB09219
    Approved

    Bisoxatin is a stimulant laxative which increases peristalsis and inhibits absorbtion of water and ions in the intestine [L926]. … It is marketed in Belgium under the tradename Wylaxine and used for the treatment of constipation and for preparation of the colon for surgical procedures.

  7. Drug

    Chlorzoxazone

    go.drugbank.com/drugs/DB00356
    Approved

    It is claimed to inhibit muscle spasm by exerting an effect primarily at the level of the spinal cord and subcortical areas of the brain. (From Martindale, The Extra Pharmacopoea, 30th ed, p1202)

  8. Drug

    Aldesleukin

    go.drugbank.com/drugs/DB00041
    ApprovedInvestigational

    This recombinant form differs from native interleukin-2 in the following ways: a) Aldesleukin is not glycosylated because it is derived from E. coli; b) the molecule has no N-terminal alanine; the codon … Aldesleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene.

  9. Drug

    Clothiapine

    go.drugbank.com/drugs/DB13256
    Approved

    Clothiapine has been approved in European countries and is an atypical antipsychotic, shown to be useful in some treatment-resistant patients.

  10. Drug

    Rauwolfia serpentina root

    go.drugbank.com/drugs/DB09363
    Investigational

    Rauwolfia (Rauwolfia serpentina), also spelled _ravolphia_, is a medicinal plant in the milkweed family. The root of the plant is ground into a powder or sold in tablets or capsules. … Reserpine is derived from Rauwolfia serpentina, and was commonly used as an antihypertensive agent in the 1950s [L1621]. Rauwolfia serpentina is also commonly referred to as _Sarpaghanda_ [A32097].